KalVista Pharmaceuticals (KALV) Net Cash Flow (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Net Cash Flow data on file, last reported at -$10.0 million in Q3 2025.

• For the quarter ending Q3 2025, Net Cash Flow fell 17194.83% year-over-year to -$10.0 million; the trailing twelve-month figure through Jul 2025 stood at -$39.7 million (down 142.59% YoY), and the FY2025 full-year result was $97.8 million, up 521.09% from the prior year.
• Net Cash Flow climbed to -$10.0 million in Q3 2025, from -$39.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $46.0 million in Q1 2023 to a low of -$39.0 million in Q2 2025.
• A 5-year average of -$1.3 million and a median of -$359500.0 in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 11866.5% in 2023 and slumped 17194.83% in 2025, its largest moves.
• Tracing KALV's Net Cash Flow over 5 years: stood at -$1.8 million in 2021, then jumped by 82.16% to -$328000.0 in 2022, then soared by 2800.91% to $8.9 million in 2023, then grew by 5.27% to $9.3 million in 2024, then plunged by 207.56% to -$10.0 million in 2025.
• Business Quant data shows KALV's Net Cash Flow at -$10.0 million in Q3 2025, -$39.0 million in Q2 2025, and $9.3 million in Q4 2024.